APO RESEARCH · REPORT
LFA-based Cardiac
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Product & engineering
Understand the product.
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
Selected research
Industry Research
LFA-based Cardiac Industry Research Report 2026
Market perspective
Lateral Flow Assay is a simple to use diagnostic device used to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, foodstuffs, or animal feeds.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
The industry's leading producers are Roche, Abbott and Siemens, with revenues of 26.24%, 16.11% and 11.04% respectively in 2019.
Read the full market overview
Report Scope
This report quantifies the global LFA-based Cardiac market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to LFA-based Cardiac.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
LFA-based Cardiac Market by Company
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
BioMérieux
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
LFA-based Cardiac Segment by Type
Troponin I
Troponin T
CK-MB
Myoglobin
Others
LFA-based Cardiac Segment by Application
Laboratory Testing
Point-of-care Testing
LFA-based Cardiac Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global LFA-based Cardiac market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of LFA-based Cardiac and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of LFA-based Cardiac.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of LFA-based Cardiac companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Troponin I
- Troponin T
- CK-MB
- Myoglobin
- Others
Applications
- Laboratory Testing
- Point-of-care Testing
Companies covered
- Roche
- Abbott
- Siemens
- Danaher
- Bio-Rad Laboratories
- BioMérieux
- Thermo Fisher
- Ortho Clinical Diagnostics
- LSI Medience Corporation
- Randox laboratories
- Wondfo Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 LFA-based Cardiac by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Troponin I
- 2.2.3 Troponin T
- 2.2.4 CK-MB
- 2.2.5 Myoglobin
- 2.2.6 Others
- 2.3 LFA-based Cardiac by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Laboratory Testing
- 2.3.3 Point-of-care Testing
- 2.4 Assumptions and Limitations
3 LFA-based Cardiac Breakdown Data by Type
- 3.1 Global LFA-based Cardiac Historic Market Size by Type (2021-2026)
- 3.2 Global LFA-based Cardiac Forecasted Market Size by Type (2027-2032)
4 LFA-based Cardiac Breakdown Data by Application
- 4.1 Global LFA-based Cardiac Historic Market Size by Application (2021-2026)
- 4.2 Global LFA-based Cardiac Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global LFA-based Cardiac Market Perspective (2021-2032)
- 5.2 Global LFA-based Cardiac Growth Trends by Region
- 5.2.1 Global LFA-based Cardiac Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 LFA-based Cardiac Historic Market Size by Region (2021-2026)
- 5.2.3 LFA-based Cardiac Forecasted Market Size by Region (2027-2032)
- 5.3 LFA-based Cardiac Market Dynamics
- 5.3.1 LFA-based Cardiac Industry Trends
- 5.3.2 LFA-based Cardiac Market Drivers
- 5.3.3 LFA-based Cardiac Market Challenges
- 5.3.4 LFA-based Cardiac Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top LFA-based Cardiac Players by Revenue
- 6.1.1 Global Top LFA-based Cardiac Players by Revenue (2021-2026)
- 6.1.2 Global LFA-based Cardiac Revenue Market Share by Players (2021-2026)
- 6.2 Global LFA-based Cardiac Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of LFA-based Cardiac Head Office and Area Served
- 6.4 Global LFA-based Cardiac Players, Product Type & Application
- 6.5 Global LFA-based Cardiac Manufacturers Established Date
- 6.6 Global LFA-based Cardiac Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America LFA-based Cardiac Market Size (2021-2032)
- 7.2 North America LFA-based Cardiac Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America LFA-based Cardiac Market Size by Country (2021-2026)
- 7.4 North America LFA-based Cardiac Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe LFA-based Cardiac Market Size (2021-2032)
- 8.2 Europe LFA-based Cardiac Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe LFA-based Cardiac Market Size by Country (2021-2026)
- 8.4 Europe LFA-based Cardiac Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific LFA-based Cardiac Market Size (2021-2032)
- 9.2 Asia-Pacific LFA-based Cardiac Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific LFA-based Cardiac Market Size by Country (2021-2026)
- 9.4 Asia-Pacific LFA-based Cardiac Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America LFA-based Cardiac Market Size (2021-2032)
- 10.2 South America LFA-based Cardiac Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America LFA-based Cardiac Market Size by Country (2021-2026)
- 10.4 South America LFA-based Cardiac Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa LFA-based Cardiac Market Size (2021-2032)
- 11.2 Middle East & Africa LFA-based Cardiac Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa LFA-based Cardiac Market Size by Country (2021-2026)
- 11.4 Middle East & Africa LFA-based Cardiac Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in LFA-based Cardiac Business (2021-2026)
- 12.1.4 Roche LFA-based Cardiac Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Abbott
- 12.2.1 Abbott Company Information
- 12.2.2 Abbott Business Overview
- 12.2.3 Abbott Revenue in LFA-based Cardiac Business (2021-2026)
- 12.2.4 Abbott LFA-based Cardiac Product Portfolio
- 12.2.5 Abbott Recent Developments
- 12.3 Siemens
- 12.3.1 Siemens Company Information
- 12.3.2 Siemens Business Overview
- 12.3.3 Siemens Revenue in LFA-based Cardiac Business (2021-2026)
- 12.3.4 Siemens LFA-based Cardiac Product Portfolio
- 12.3.5 Siemens Recent Developments
- 12.4 Danaher
- 12.4.1 Danaher Company Information
- 12.4.2 Danaher Business Overview
- 12.4.3 Danaher Revenue in LFA-based Cardiac Business (2021-2026)
- 12.4.4 Danaher LFA-based Cardiac Product Portfolio
- 12.4.5 Danaher Recent Developments
- 12.5 Bio-Rad Laboratories
- 12.5.1 Bio-Rad Laboratories Company Information
- 12.5.2 Bio-Rad Laboratories Business Overview
- 12.5.3 Bio-Rad Laboratories Revenue in LFA-based Cardiac Business (2021-2026)
- 12.5.4 Bio-Rad Laboratories LFA-based Cardiac Product Portfolio
- 12.5.5 Bio-Rad Laboratories Recent Developments
- 12.6 BioMérieux
- 12.6.1 BioMérieux Company Information
- 12.6.2 BioMérieux Business Overview
- 12.6.3 BioMérieux Revenue in LFA-based Cardiac Business (2021-2026)
- 12.6.4 BioMérieux LFA-based Cardiac Product Portfolio
- 12.6.5 BioMérieux Recent Developments
- 12.7 Thermo Fisher
- 12.7.1 Thermo Fisher Company Information
- 12.7.2 Thermo Fisher Business Overview
- 12.7.3 Thermo Fisher Revenue in LFA-based Cardiac Business (2021-2026)
- 12.7.4 Thermo Fisher LFA-based Cardiac Product Portfolio
- 12.7.5 Thermo Fisher Recent Developments
- 12.8 Ortho Clinical Diagnostics
- 12.8.1 Ortho Clinical Diagnostics Company Information
- 12.8.2 Ortho Clinical Diagnostics Business Overview
- 12.8.3 Ortho Clinical Diagnostics Revenue in LFA-based Cardiac Business (2021-2026)
- 12.8.4 Ortho Clinical Diagnostics LFA-based Cardiac Product Portfolio
- 12.8.5 Ortho Clinical Diagnostics Recent Developments
- 12.9 LSI Medience Corporation
- 12.9.1 LSI Medience Corporation Company Information
- 12.9.2 LSI Medience Corporation Business Overview
- 12.9.3 LSI Medience Corporation Revenue in LFA-based Cardiac Business (2021-2026)
- 12.9.4 LSI Medience Corporation LFA-based Cardiac Product Portfolio
- 12.9.5 LSI Medience Corporation Recent Developments
- 12.10 Randox laboratories
- 12.10.1 Randox laboratories Company Information
- 12.10.2 Randox laboratories Business Overview
- 12.10.3 Randox laboratories Revenue in LFA-based Cardiac Business (2021-2026)
- 12.10.4 Randox laboratories LFA-based Cardiac Product Portfolio
- 12.10.5 Randox laboratories Recent Developments
- 12.11 Wondfo Biotech
- 12.11.1 Wondfo Biotech Company Information
- 12.11.2 Wondfo Biotech Business Overview
- 12.11.3 Wondfo Biotech Revenue in LFA-based Cardiac Business (2021-2026)
- 12.11.4 Wondfo Biotech LFA-based Cardiac Product Portfolio
- 12.11.5 Wondfo Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst